- Home
- ENSC vs ONFO Comparison
ENSC vs ONFO Comparison
Compare ENSC & ONFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- ONFO
- Stock Information
- Founded
- ENSC 2003
- ONFO 2018
- Country
- ENSC United States
- ONFO United States
- Employees
- ENSC N/A
- ONFO N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- ONFO Computer Software: Programming Data Processing
- Sector
- ENSC Health Care
- ONFO Technology
- Exchange
- ENSC Nasdaq
- ONFO Nasdaq
- Market Cap
- ENSC 5.2M
- ONFO 5.2M
- IPO Year
- ENSC N/A
- ONFO 2022
- Fundamental
- Price
- ENSC $2.14
- ONFO $1.02
- Analyst Decision
- ENSC
- ONFO
- Analyst Count
- ENSC 0
- ONFO 0
- Target Price
- ENSC N/A
- ONFO N/A
- AVG Volume (30 Days)
- ENSC 84.6K
- ONFO 26.1K
- Earning Date
- ENSC 08-13-2025
- ONFO 08-14-2025
- Dividend Yield
- ENSC N/A
- ONFO N/A
- EPS Growth
- ENSC N/A
- ONFO N/A
- EPS
- ENSC N/A
- ONFO N/A
- Revenue
- ENSC $7,413,722.00
- ONFO $10,508,728.00
- Revenue This Year
- ENSC N/A
- ONFO N/A
- Revenue Next Year
- ENSC $1,354.55
- ONFO N/A
- P/E Ratio
- ENSC N/A
- ONFO N/A
- Revenue Growth
- ENSC 415.58
- ONFO 78.36
- 52 Week Low
- ENSC $1.62
- ONFO $0.61
- 52 Week High
- ENSC $14.67
- ONFO $1.88
- Technical
- Relative Strength Index (RSI)
- ENSC 51.93
- ONFO 46.27
- Support Level
- ENSC $2.03
- ONFO $0.93
- Resistance Level
- ENSC $2.21
- ONFO $1.03
- Average True Range (ATR)
- ENSC 0.09
- ONFO 0.06
- MACD
- ENSC 0.01
- ONFO -0.00
- Stochastic Oscillator
- ENSC 63.38
- ONFO 52.94
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place. The company operates in two business segments: Business to Business (B2B) and Business to Consumers (B2C). The majority of its revenue is generated from the Business-to-Business (B2B) segment, which includes the results of operations of Eastern Standard, RevenueZen, DDS Rank, SEO Butler, Contentellect, DealPipe, and Onfolio LLC.